Upcoming Milestones over remainder of 2018

If the share price moves a lot higher its because the share price is UNDERVALUED. Just putting it out there before the illinformed start calling for please explains. Multiple Late Stage commercialization opportunities with accelerated to market potential via favourable regulatory provisions.

UPCOMING MILESTONES

The Company expects multiple key inflection points over the remainder of the 2018 financial year, including:

• completion of enrollment in Q4 CY2017 in the Phase 3 trial evaluating MSC-100-IV in children with aGVHD;

• the trial’s 28-day primary endpoint data is expected in Q1 CY2018 and the 100-day survival result is expected in Q2 CY2018;

• completion of enrollment in early Q1 CY2018 in the Phase 3 trial evaluating MPC-06-ID in patients with chronic low back pain;

• the 6-month primary endpoint in Q1 CY2018 for the fully-enrolled Phase 3 trial evaluating MPC-150-IM in NYHA Class IV patients with advanced heart failure, with full 12-month study results expected in Q3 CY2018; and

• completion of enrollment in 2H CY2018 in the Phase 3 trial evaluating MPC-150-IM in NYHA Class III patients with advanced heart failure

GET SET